ScripLes Laboratoires Servier is on a mission to add some spark to its neuroscience pipeline by developing RNA-targeting drugs for neurodegenerative conditions as it tries to follow in the footsteps of th
ScripNeuron23 Inc. aims to take two small molecule drug candidates for neurological diseases into the clinic during the next two years, with $100m from a series C venture capital round that the company an
ScripScrip regularly covers business development and deal-making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. I-Mab Readies For Commercial Activity V
In VivoThe development of therapies for Parkinson’s disease should have been a triumph long ago for medical science. Degeneration of dopaminergic nerves in the central nervous system (CNS) was identified as